Medlive Technology Future Growth
Future criteria checks 1/6
Medlive Technology's earnings are forecast to decline at 7.2% per annum while its annual revenue is expected to grow at 13.9% per year. EPS is expected to decline by 7.1% per annum. Return on equity is forecast to be 4.1% in 3 years.
Key information
-7.2%
Earnings growth rate
-7.1%
EPS growth rate
Healthcare Services earnings growth | 29.3% |
Revenue growth rate | 13.9% |
Future return on equity | 4.1% |
Analyst coverage | Low |
Last updated | 29 Mar 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 774 | 239 | 138 | 189 | 3 |
12/31/2025 | 637 | 211 | 122 | 145 | 3 |
12/31/2024 | 517 | 240 | 78 | 161 | 3 |
12/31/2023 | 412 | 242 | 69 | 102 | N/A |
9/30/2023 | 384 | 216 | 69 | 90 | N/A |
6/30/2023 | 356 | 189 | 69 | 79 | N/A |
3/31/2023 | 335 | 153 | 69 | 78 | N/A |
12/31/2022 | 314 | 117 | 70 | 77 | N/A |
9/30/2022 | 300 | 83 | 51 | 57 | N/A |
6/30/2022 | 286 | 48 | 32 | 36 | N/A |
3/31/2022 | 285 | 44 | 37 | 40 | N/A |
12/31/2021 | 284 | 41 | 42 | 44 | N/A |
9/30/2021 | 270 | 55 | 71 | 73 | N/A |
6/30/2021 | 255 | 70 | 100 | 101 | N/A |
3/31/2021 | 234 | 78 | 105 | 106 | N/A |
12/31/2020 | 214 | 85 | 110 | 111 | N/A |
12/31/2019 | 122 | 31 | 26 | 28 | N/A |
12/31/2018 | 83 | 14 | 19 | 22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2192's earnings are forecast to decline over the next 3 years (-7.2% per year).
Earnings vs Market: 2192's earnings are forecast to decline over the next 3 years (-7.2% per year).
High Growth Earnings: 2192's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 2192's revenue (13.9% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 2192's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2192's Return on Equity is forecast to be low in 3 years time (4.1%).